New hope for pancreatic cancer: drug combo shows promise in early trial

NCT ID NCT04888312

Ongoing Disease control Sponsor: Alligator Bioscience AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called mitazalimab combined with standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal is to see if the combination is safe and can shrink tumors. About 94 adults who have not had prior chemotherapy for this cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque,

Bordeaux, France
Centre Lyon Berard

Lyon, France
Cliniques Universitaires St-Luc

Brussels, Belgium
Hopital Européen Georges Pompidou

Paris, 75015, France
Hospital Erasme

Brussels, Belgium
Hospital Universitario La Paz, Madrid, Spain

Madrid, Spain
Hospital Universitario Miguel Servet, Zaragoza, Spain

Zaragoza, Spain
Hospital Universitario Ramon y Cajal, Madrid, Spain

Madrid, Spain
Hospital Universitario Vall d'Hebron, Barcelona, Spain

Barcelona, Spain
Hospital Universitario Virgen del Rocio, Sevilla, Spain

Seville, Spain
Institut Paoli-Calmettes

Marseille, France
Institute de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France
UZA Antwerp

Edegem, Belgium
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.